The recent Pfizer CEO controversy raises the question of whether additional regulations are needed to restore public trust in the pharmaceutical industry.

Pfizer's CEO, Albert Bourla, is facing scrutiny in the United Kingdom (UK) due to comments he made last year during an interview with the BBC about Pfizer's COVID vaccine indication for children. In December 2021, Bourla stated, “there is no doubt in my mind that the benefits, completely, are in favor of” vaccinating five-year-olds. England had not yet approved the vaccination at the time of this statement.

UsForThem, a children's advocacy group, filed a complaint with the UK's Prescription Medicines Code of Practice Authority (PMCPA) last year, accusing Bourla of making "disgracefully misleading" statements during the BBC interview, including one that "COVID in schools is thriving.” The PMCPA is an independent self-regulatory organization established by the Association of the British Pharmaceutical Industry (ABPI) to administer the ABPI Code of Practice for the Pharmaceutical Industry. In addition to providing advice, guidance, and training on the Code, the authority is also responsible for resolving complaints. As part of its duties, the PMCPA facilitates conflict resolution between companies and arranges regular scrutiny of advertising.

UsForThem wrote a letter to the PMCPA stating Bourla's comments, including "immunizing that age group [children under the age of 11] in the UK and Europe would be a very good idea,” violated multiple clauses within the code. On page 44 of the 2021 PMPCA code, clause 26.1 states, "Prescription only medicines must not be advertised to the public. This prohibition does not apply to vaccination and other campaigns carried out by companies and approved by the health ministers." Bourla's remarks did not receive prior approval from the health minister and consequently violated the PMCPA code.

The case calls into question whether the U.S. needs additional regulations to protect the public's health. Currently, the United States (U.S.) does not have laws prohibiting the advertisement of prescription drugs, and pharmaceutical companies advertise through all media outlets and social channels. Although the Food and Drug Administration (FDA) has issued guidelines for social media use by industry, it leaves the advertising market of U.S. pharmaceutical companies largely unregulated.

While the PhRMA code regulates how industry and healthcare providers interact in the U.S., should a new regulatory body establish more precise boundaries for pharmaceutical companies to market to consumers in the U.S.? As the Pfizer CEO case evolves, its results may inform how pharmaceutical companies handle media in the future.